Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components.
Hematologic toxicity limits the radioactivity that may be administered for radiolabeled antibody therapy. This work examines approaches for obtaining biodistribution data and performing dosimetry when the administered antibody is known to bind to a cellular component of blood, bone, or marrow. Marrow dosimetry in this case is more difficult because the kinetics of antibody clearance from the blood cannot be related to the marrow. Several approaches for obtaining antibody kinetics in the marrow are examined and evaluated. The absorbed fractions and S factors that should be used in performing marrow dosimetry are also examined and the effect of including greater anatomical detail is considered. The radiobiology of the red marrow is briefly reviewed. Recommendations for performing marrow dosimetry when the antibody binds to the marrow are provided.
Sgouros
G
G
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. sgourosg@mskcc.org
Stabin
M
M
Erdi
Y
Y
Akabani
G
G
Kwok
C
C
Brill
A B
AB
Wessels
B
B
D001769:Blood / Q000528:radiation effects*; D001853:Bone Marrow / Q000502:physiology / Q000528:radiation effects*; D001842:Bone and Bones / Q000528:radiation effects*; D006801:Humans; D007700:Kinetics; D008962:Models, Theoretical; D019047:Phantoms, Imaging; D011868:Radioisotopes / Q000493:pharmacokinetics*; D011874:Radiometry / Q000379:methods*; D011877:Radionuclide Imaging; D015203:Reproducibility of Results
D011868:Radioisotopes